Flash Finance

Torrent Pharmaceuticals LimitedTORNTPHARMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹4,558.90
MCap ₹173,406 Cr · P/E 81.3
Torrent Pharmaceuticals Limited — Stock analysis & AI research Torrent Pharmaceuticals Limited — Multibagger AI analysis Torrent Pharmaceuticals Limited — Seasonality — best & worst months Torrent Pharmaceuticals Limited — Technical indicators & charts Torrent Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Torrent Pharmaceuticals Limited — Descending Channel pattern forming Torrent Pharmaceuticals Limited — Live exchange announcements
📋 High ROE Stocks📋 High Operating Margin Stocks📋 Large Cap Stocks List ⚖️ vs Gland Pharma⚖️ vs Ajanta Pharma 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4,158 Cr
Sales · Jun 2026
+58.9% YoY
₹1,573 Cr
Operating Profit · Jun 2026
+60.7% YoY
37.8%
OPM % · Jun 2026
+1.1% YoY
₹492 Cr
Net Profit · Jun 2026
-10.7% YoY
₹12.94
EPS · Jun 2026
-20.5% YoY

📝 Torrent Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Torrent Pharmaceuticals Limited reported revenue of ₹4,158 crore for the quarter ended June 2026 (Q1 FY27), up 58.9% from ₹2,616 crore in the same quarter last year, and up 52.0% sequentially over the March 2026 quarter.

Net profit fell 10.7% year-on-year to ₹492 crore, from ₹551 crore. Earnings per share (EPS) came in at ₹12.94.

Operating profit stood at ₹1,573 crore — an operating margin (OPM) of 37.8%, compared with 37.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Torrent Pharmaceuticals Limited posted revenue of ₹10,712 crore, a growth of 10.6% over FY25, with a net profit of ₹2,192 crore (up 16.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹12,254 crore with a net profit of ₹2,133 crore.

Valuation snapshot

At the current price of ₹4,558.90, TORNTPHARM has a market capitalisation of ₹173,406 crore and a trailing P/E of about 81.3.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 3rd-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 60.78%, foreign institutional investors (FIIs) 17.22%, domestic institutional investors (DIIs) 13.46%, public shareholders 8.54% of Torrent Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹173,406 Cr
Current Price ?
₹4,558.9
P/E ?
81.30above ind
Industry P/E ?
35.00
P/B ?
20.52
P/S ?
14.15
P/FCF ?
76.66
Enterprise Value ?
₹187,683 Cr
EV/EBITDA ?
40.38
PEG ?
2.80
Earnings Yield ?
1.9%
Dividend Yield ?
0.83%
Profitability & Returns
Sales (TTM) ?
₹12,254 Cr
OPM ?
37.9%
Profit after tax (TTM) ?
₹2,133 Cr
EPS (TTM) ?
₹56.08
ROCE ?
20.0%
ROE ?
25.2%
ROA ?
8.3%
Growth
Sales — latest qtr ?
₹4,158 Cr
PAT — latest qtr ?
₹492 Cr
YoY qtr sales growth ?
58.9%
YoY qtr profit growth ?
-10.7%
Sales growth (3y) ?
12%
Sales growth (5y) ?
11%
Profit growth (3y) ?
29%
Profit growth (5y) ?
14%
Financial Health
Debt ?
₹14,277 Cr
Debt to Equity ?
1.69
Interest Coverage ?
9.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
60.78%
Change in promoter holding ?
-7.53%
Pledged percentage ?
N/A
Market
Return 3 months ?
-4.3%
Return 6 months ?
9.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,8571,9202,1212,1462,1232,1432,4382,4342,3772,4332,6162,7622,5992,7354,158 +58.9% +52.0%
Operating Profit 5855787377367017168999218878689791,0721,0001,0031,573 +60.7% +56.8%
Other Income 15261115-117621-7315-5-27-811-21 -320.0% -290.9%
Interest 91949077696764544847453734225293 +551.1% +30.2%
Depreciation 156182183192191195189190191190187189191197575 +207.5% +191.9%
Profit Before Tax 353328475482430530667670651622742806757592663 -10.6% +12.0%
Net Profit 229219323327297410469460485474551597577467492 -10.7% +5.4%
EPS 6.786.469.559.658.7812.1213.8613.6014.3314.0016.2817.6417.0413.8012.94 -20.5% -6.2%
OPM % 31.5% 30.1% 34.7% 34.3% 33.0% 33.4% 36.9% 37.8% 37.3% 35.7% 37.4% 38.8% 38.5% 36.7% 37.8% +1.1% +3.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,682 Cr ₹10,712 Cr ₹12,254 Cr +10.6%
Operating Profit ₹3,575 Cr ₹4,054 Cr ₹4,648 Cr +13.4%
OPM % 36.92% 37.85% 37.93% +2.5%
NPM % 19.50% 20.46% 17.41% +4.9%
Other Income ₹32 Cr ₹-29 Cr ₹-45 Cr -190.6%
Depreciation ₹760 Cr ₹764 Cr ₹1,152 Cr +0.5%
Interest ₹213 Cr ₹341 Cr ₹589 Cr +60.1%
EBIT ₹2,815 Cr ₹3,290 Cr ₹3,496 Cr +16.9%
PBT ₹2,610 Cr ₹2,897 Cr ₹2,818 Cr +11.0%
Tax ₹722 Cr ₹580 Cr ₹560 Cr -19.7%
Net Profit ₹1,888 Cr ₹2,192 Cr ₹2,133 Cr +16.1%
EPS ₹55.79 ₹64.76 ₹61.42 +16.1%
Material Cost ₹2,250 Cr ₹1,744 Cr ₹2,063 Cr -22.5%
Employee Cost ₹1,636 Cr ₹1,392 Cr ₹1,616 Cr -14.9%
Extraordinary Items ₹24 Cr ₹-3 Cr ₹18 Cr -112.5%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 169169169169 +0.0%
Reserves 6,2876,6607,4238,283 +11.6%
Borrowings 4,5753,3442,62914,277 +443.1%
Other Liabilities 1,8402,2042,6203,085 +17.7%
Total Liabilities 12,87212,37712,84225,814 +101.0%
Fixed Assets 7,9727,9867,5547,370 -2.4%
CWIP 698226402420 +4.5%
Investments 36146352313,172 +2418.5%
Other Assets 3,8413,7014,3634,851 +11.2%
Total Assets 12,87212,37712,84225,814 +101.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2,2652,8932,5742,731 +6.1%
Cash from Investing Activity -2,326-296-470-12,990 -2663.8%
Cash from Financing Activity 81-2,578-2,10410,225 +586.0%
Net Cash Flow 2019-0-34 —
Free Cash Flow 1,8502,5802,1462,262 +5.4%
CFO/OP 103%111%86%85% -1.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 82678290 +9.8%
Inventory Days 273268254241 -5.1%
Days Payable 104130125127 +1.6%
Cash Conversion Cycle 251205211204 -3.3%
Working Capital Days 1022433 -93.0%
ROCE % 18%21%28%20% -28.6%

👥 Shareholding (latest 6 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026Sep 2026 % Chg
Promoters 68.31%68.31%68.31%68.31%60.78%60.78% +0.0%
FIIs 15.92%16.13%16.18%15.44%17.97%17.22% -4.2%
DIIs 9.17%9.05%8.96%9.83%12.87%13.46% +4.6%
Government 0.10%0.10%0.00%——— —
Public 6.47%6.41%6.55%6.42%8.38%8.54% +1.9%
No. of Shareholders 78,22676,21483,81185,7761,40,5991,42,140 +1.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Torrent Pharmaceuticals Limited's revenue in Q1 FY27?
Torrent Pharmaceuticals Limited reported revenue of ₹4,158 crore for the quarter ended June 2026 (Q1 FY27), up 58.9% from ₹2,616 crore in the same quarter last year, and up 52.0% sequentially over the March 2026 quarter.
What was Torrent Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit fell 10.7% year-on-year to ₹492 crore, from ₹551 crore. Earnings per share (EPS) came in at ₹12.94.
What is TORNTPHARM's market capitalisation and P/E ratio?
At the current price of ₹4,558.90, TORNTPHARM has a market capitalisation of ₹173,406 crore and a trailing P/E of about 81.3.
Who owns Torrent Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 60.78%, foreign institutional investors (FIIs) 17.22%, domestic institutional investors (DIIs) 13.46%, public shareholders 8.54% of Torrent Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI